Loxo Oncology announces completion of clinical trial enrollment for larotrectinib NDA
Loxo Oncology announced the company has completed clinical trial enrollment for the larotrectinib NDA primary efficacy analysis. This determination is based on written feedback from the FDA which affirmed the target enrollment goal for the primary efficacy analysis data set to support an NDA filing. February 21, 2017